Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Merck (NYSE:MRK) shares inched higher on Friday after Summit Therapeutics (NASDAQ:SMMT) announced the latest survival data ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Purdue University scientists have identified the Supinoxin molecule as a possible new therapy for small cell lung cancer.

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...

NSCLC patients who stopped immunotherapy due to side effects still showed lasting disease control and survival benefits..

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.

Lung Cancer Test Predicts Survival in Early Stages Better Than ... that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and ...